-$0.12 EPS Expected for Aethlon Medical, Inc. (NASDAQ:AEMD) This Quarter

Equities analysts expect Aethlon Medical, Inc. (NASDAQ:AEMDGet Rating) to post ($0.12) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Aethlon Medical’s earnings, with estimates ranging from ($0.16) to ($0.08). Aethlon Medical reported earnings per share of ($0.15) in the same quarter last year, which would suggest a positive year over year growth rate of 20%. The company is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Aethlon Medical will report full year earnings of ($0.58) per share for the current financial year, with EPS estimates ranging from ($0.62) to ($0.54). For the next year, analysts anticipate that the firm will report earnings of $2.46 per share. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Aethlon Medical.

A number of brokerages have weighed in on AEMD. Maxim Group lowered their price objective on Aethlon Medical from $11.00 to $4.00 in a report on Tuesday, February 15th. StockNews.com started coverage on Aethlon Medical in a report on Saturday. They issued a “sell” rating for the company.

Shares of NASDAQ AEMD traded up $0.20 during mid-day trading on Friday, hitting $1.31. The company had a trading volume of 3,168,081 shares, compared to its average volume of 83,751. Aethlon Medical has a 1-year low of $0.88 and a 1-year high of $12.49. The company has a market capitalization of $20.19 million, a PE ratio of -2.18 and a beta of 0.81. The business’s 50-day simple moving average is $1.25 and its 200 day simple moving average is $1.68.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. NTB Financial Corp purchased a new stake in Aethlon Medical during the 4th quarter worth $32,000. Jane Street Group LLC purchased a new stake in Aethlon Medical during the 3rd quarter worth $101,000. Bank of New York Mellon Corp purchased a new position in Aethlon Medical in the 3rd quarter valued at about $111,000. Renaissance Technologies LLC purchased a new position in Aethlon Medical in the 3rd quarter valued at about $196,000. Finally, BlackRock Inc. boosted its position in Aethlon Medical by 771.7% in the 3rd quarter. BlackRock Inc. now owns 73,074 shares of the medical equipment provider’s stock valued at $282,000 after buying an additional 64,691 shares during the last quarter. 10.58% of the stock is owned by institutional investors.

About Aethlon Medical (Get Rating)

Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.

Further Reading

Get a free copy of the Zacks research report on Aethlon Medical (AEMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.